摘要
目的探讨生长激素在首次体外受精-胚胎移植（IVF—ET）失败患者再次行IVF—ET治疗周期中的应用价值。方法选择首次IVF-ET胚胎种植失败再次行IVF-ET治疗的68例患者，所有患者第一周期及现周期均采用常规长方案降调节，现周期自降调日予生长激素（GH）4U／d直至胚胎移植前1d，作为研究组；未使用生长激素的第一周期作为对照组。比较两组的MⅡ卵子数、受精率、卵裂率、优质胚胎率、妊娠率。结果研究组优质胚胎率、妊娠率分别为46．26％和26．77％，而对照组分别为33．58％和0，两组差异有统计学意义（X^2=3．97，4．86，均P〈0．05）；而MⅡ卵子数、卵裂率、受精率无显著增加（P〉0．05）。结论对首次行IVF-ET失败的患者再次行IVF．ET治疗时使用生长激素，可提高优质胚胎率，改善妊娠结局，有一定的临床应用价值。
Objective To study the application value of growth hormone in the renewal cycle for those patients who were failed in the first IVE-ET treatment. Methods 68 patients who were failed in the previous IVE-ET treatment were divided into two groups and were given long term down-regulating protocol in the first cycle and current cycle. The study group consisted of eases with using GH （4U/d）from the day of down-regulating till the day before embryo transfer and control group consisted of those without using GH. Results The rate of pregnancy of study group and control group was 26.77% and 0, while the rate of quality embryos was 46.26% and 33.58%, respectively. There was significant difference between the two groups （ X^2 = 3.97,4.86, P 〈 0.05 ）, while there was no significant effect on the rate of fertilization and cleavage, the number of M Ⅱ oocytes retrieved （ all P 〉 0.05 ）. Conclusion In the second cycle ,growth hormone could improve the clinical pregnancy rate and the rate of quality embryos for those pa-tients who were failed in the first IVE-ET treatment.
出处
《中国基层医药》
CAS
2011年第8期1028-1029,共2页
Chinese Journal of Primary Medicine and Pharmacy
